Phase III Randomized Trial of Calendula Officinalis Compared With Trolamine for the Prevention of Acute Dermatitis During Irradiation for Breast Cancer
Top Cited Papers
- 15 April 2004
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (8) , 1447-1453
- https://doi.org/10.1200/jco.2004.07.063
Abstract
Purpose: The effectiveness of nonsteroid topical agents for the prevention of acute dermatitis during adjuvant radiotherapy for breast carcinoma has not been demonstrated. The goal of this study was to compare the effectiveness of calendula (Pommade au Calendula par Digestion; Boiron Ltd, Levallois-Perret, France) with that of trolamine (Biafine; Genmedix Ltd, France), which is considered in many institutions to be the reference topical agent. Patients and Methods: Between July 1999 and June 2001, 254 patients who had been operated on for breast cancer and who were to receive postoperative radiation therapy were randomly allocated to application of either trolamine (128 patients) or calendula (126 patients) on the irradiated fields after each session. The primary end point was the occurrence of acute dermatitis of grade 2 or higher. Prognostic factors, including treatment modalities and patient characteristics, were also investigated. Secondary end points were the occurrence of pain, the quantity of topical agent used, and patient satisfaction. Results: The occurrence of acute dermatitis of grade 2 or higher was significantly lower (41% v 63%; P < .001) with the use of calendula than with trolamine. Moreover, patients receiving calendula had less frequent interruption of radiotherapy and significantly reduced radiation-induced pain. Calendula was considered to be more difficult to apply, but self-assessed satisfaction was greater. Body mass index and adjuvant chemotherapy before radiotherapy after lumpectomy were significant prognostic factors for acute dermatitis. Conclusion: Calendula is highly effective for the prevention of acute dermatitis of grade 2 or higher and should be proposed for patients undergoing postoperative irradiation for breast cancer.Keywords
This publication has 22 references indexed in Scilit:
- Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind studyBritish Journal of Dermatology, 2002
- Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized studyPublished by Elsevier ,2001
- Topical Biafine and Lipiderm for the prevention of radiation dermatitis: a randomized prospective trial.Oncology Reports, 2001
- The impact of skin washing with water and soap during breast irradiation: a randomized studyRadiotherapy and Oncology, 2001
- Randomized phase III study comparing best supportive care to biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation therapy oncology group (RTOG) 97-13International Journal of Radiation Oncology*Biology*Physics, 2000
- Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centersInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapyRadiotherapy and Oncology, 1997
- Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancerRadiotherapy and Oncology, 1996
- Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicityInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Skin Protection by Sucralfate Cream During Electron Beam TherapyActa Oncologica, 1994